Evidence map›Paper›PMID 42457718›Full record

ArticleNature communications2026

Induced ubiquitination of the partially disordered estrogen receptor alpha via a 14-3-3 directed molecular glue-PROTAC.

Carlo J A Verhoef, Charlotte Crowe, Mark A Nakasone, Aitana DeLaCuadra-Basté, Tessa Harzing, Naomi A S Span, Gajanan Sathe, Laura C Demmers, Kentaro Iso, Christian Ottmann and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carlo J A Verhoef *Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID http://orcid.org/0000-0001-5720-1602
Charlotte Crowe *Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0003-2068-8255
Mark A NakasoneCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-1362-191X
Aitana DeLaCuadra-BastéCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK.
Tessa HarzingLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.
Naomi A S SpanLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.
Gajanan SatheCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-6239-5365
Laura C DemmersAmbagon Therapeutics, Catalyst Business Center, Eindhoven, Netherlands.
Kentaro IsoCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK.
Christian OttmannLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID http://orcid.org/0000-0001-7315-0315
Luc BrunsveldLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.ORCID http://orcid.org/0000-0001-5675-511X
Alessio CiulliCentre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK. a.ciulli@dundee.ac.uk.ORCID http://orcid.org/0000-0002-8654-1670
Peter J CossarLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands. pcossar001@dundee.ac.uk.ORCID http://orcid.org/0000-0002-8260-5710

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101098234Innovative Medicines Initiative (IMI) 875510 (EUbOPEN)Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) OCenW.M20.200Netherlands Organisation for Scientific Research | Stichting voor de Technische Wetenschappen (Technology Foundation STW) VI.Veni.212.27RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M010996/1RCUK | Medical Research Council (MRC) MR/R015791Royal Society URF\R1\251609
6 · The paper itself

Abstract

Proteins lacking defined ligandable pockets remain challenging drug targets. Here, we develop a molecular glue-based PROTAC (

Indexed as

14-3-3 ProteinsEstrogen Receptor alphaUbiquitinationCryoelectron MicroscopyHumansLigandsMolecular Dynamics SimulationProtein BindingProteolysis Targeting ChimeraVon Hippel-Lindau Tumor Suppressor Protein14-3-3 ProteinsESR1 protein, humanEstrogen Receptor alphaLigandsProteolysis Targeting ChimeraVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID42457718
PMCPMC13490399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.